Anavex Life Sciences Corp (AVXL)

[XenaLives]

CTAD 2018 info archived:

Poster available during the duration of CTAD:
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1 , Michael Kornhauser BPharm1 , Ella Modini BSc1 , Harald Hampel, MD PhD2 , Stephan Toutain MS3, Christopher Missling PhD3

Friday, October 26 - Late Breaking Session
3.30 - 3.45 p.m. LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1 , Mohammad Afshar, MD, PhD2 , Frédéric Parmentier, PhD2 , Coralie Williams, MSc2 , Adrien Etcheto, MSc2 , Federico Goodsaid, PhD3 , Christopher U Missling, PhD4
****Information on Federico Goodsaid,Regulatory Pathfinders
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143696879
https://www.linkedin.com/in/regulatorypathfinders (Thanks blanka)

Saturday, October 27- Oral communications:
1.30 - 1.45 p.m. OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation Gustavo A. Jimenez-Maggiora, MBA1 , Rema Raman, PhD1 , Michael S. Rafii, MD, PhD1 , Reisa Anne Sperling, MD2,3, Jeffrey Lee Cummings, MD4, Paul S. Aisen, MD1

Slides from 2018 CTAD:
https://www.anavex.com/wp-content/uploads/2018/10/ANAVEX2-73_CTAD_2018_Presentation.pdf

Slide 16 shows good response in those with ApoE4 variant even though it is expected to be associated with faster rate of AD progression:
https://www.nature.com/articles/tpj200958
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144500445

Investor2014 on CTAD slides
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242

CTAD overviews:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144493744
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242

Some CTAD coverage: